Last reviewed · How we verify
NCT04978740
Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)
NA trial testing Ophthalmological examination in Mast Cell Activation Disease in 21 participants. Completed in 3 September 2021.
3 September 2021
Quick facts
| Lead sponsor | Poitiers University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 21 |
| Start date | 30 July 2021 |
| Primary completion | 3 September 2021 |
| Estimated completion | 3 September 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- Ophthalmological examination
Conditions studied
- Mast Cell Activation Disease — all drugs for Mast Cell Activation Disease →
- Mast Cell Activation Syndrome — all drugs for Mast Cell Activation Syndrome →
- Mast Cell Disease — all drugs for Mast Cell Disease →
- Urticaria Pigmentosa — all drugs for Urticaria Pigmentosa →
Sponsor
Poitiers University Hospital
Who can join
18 and older, any sex, with Mast Cell Activation Disease or Mast Cell Activation Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the general population is 1 in 10,000. This pathology is due to the proliferation of a mast cell clone and the excessive release of inflammatory mediators which lead to abnormal tissue infiltration. To date, there are only a few cases reporting ocular and orbital manifestations of mastocytosis. Our prospective, interventional and single-center study consist in describing the ocular functional manifestations and ocular surface abnormalities of patients with systemic and cutaneous mastocytosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04978740
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ophthalmological examination
Trials testing the same drug.
- NCT03459508 — Ocular Findings in Women With Primary Antiphospholipid Syndrome · completed
Other Poitiers University Hospital trials
Trials by the same sponsor.
- NCT07350291 — Evaluation of the Diagnostic Capabilities of Saliva Samples From Pediatric Patients, Promoting Active Involvement of the · NA · not yet recruiting
- NCT07411651 — Confirmation of the Link Between Endocrine Disruptors Exposure and Breast Cancer and Identification of Biological Respon · NA · not yet recruiting
- NCT07463963 — Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febr · NA · not yet recruiting
- NCT07475442 — Prognostic Factors of Hospitalization for Patients Aged 75 and Over in Emergency Department in France - Monocentric Retr · not yet recruiting
- NCT07412717 — The Efficacy of Combining Music Intervention With Nicotine Replacement Therapy to Reduce Smoking Craving, Among Healthca · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04978740 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Poitiers University Hospital
- Last refreshed: 1 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04978740.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing